Screener
Viridian Therapeutics, Inc. VRDN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed November 12, 2024. Open the filing →
- Filed
- Nov 12, 2024
- Fiscal quarter
- Q3 FY2024
- Calendar quarter
- Q3 2024
- Accession
- 0001590750-24-000023
FAQ
- What is Viridian Therapeutics, Inc.'s EPS (diluted)?
- Viridian Therapeutics, Inc. (VRDN) reported EPS (diluted) of -$1.15 in Q3 2024.
- How has Viridian Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Viridian Therapeutics, Inc.'s EPS (diluted) decreased by 5.5% year-over-year, from -$1.09 to -$1.15.
- What is the long-term trend for Viridian Therapeutics, Inc.'s EPS (diluted)?
- Over 2 years (2021 to 2023), Viridian Therapeutics, Inc.'s EPS (diluted) has grown at a -13.4% compound annual growth rate (CAGR), from -$7.08 to -$5.31.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Viridian Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude